Suppression of emergence of resistance in pathogenic bacteria: Keeping our powder dry, part 1

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1183-1193

  Drusano, G L ^a   Louie, Arnold ^a   MacGowan, Alasdair ^b   Hope, William ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; MOXIFLOXACIN; RIFAMPICIN; ANTIINFECTIVE AGENT;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BIOLOGICAL ACTIVITY; DRUG EXPOSURE; DRUG INDUSTRY; ENTEROBACTERIACEAE; INFECTION CONTROL; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SUSCEPTIBLE POPULATION; TREATMENT DURATION; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MICROBIOLOGY; MULTIDRUG RESISTANCE; MUTATION; PATHOGENICITY; TIME FACTOR;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; HUMANS; MUTATION; PSEUDOMONAS AERUGINOSA; TIME FACTORS;

EID: 84960154061     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02177-15     Document Type: Article

References (53)

1. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J, Jr, Infectious Diseases Society of America. 2008. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46:155-164. http://dx.doi.org/10.1086/524891.
2. Davies SC. 2013. Infections and the rise of antimicrobial resistance. Annual report of the Chief Medical Officer, vol 2, 2011. Department of Health, London, United Kingdom.
3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
4. Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) Division of Healthcare Quality Promotion (DHQP). 2014. Public health action plan to combat antimicrobial resistance. Centers for Disease Control and Prevention, Atlanta, GA.
5. Innovative Medicines Initiative. 2010. COMBACTE (Combating Bacterial Resistance in Europe). Innovative Medicines Initiative, Brussels, Belgium. http://www.imi.europa.eu/content/combacte.
6. Allerberger F, Gareis R, Jindrak V, Struelens MJ. 2009. Antibiotic stewardship implementation in the EU: the way forward. Expert Rev Anti Infect Ther 7:1175-1183. http://dx.doi.org/10.1586/eri.09.96.
7. Tam VH, Louie A, Deziel MR, Liu W, Drusano GL. 2007. The relationship between quinolone exposures and resistance amplification is characterized by an inverted-U: a new paradigm for optimizing pharmacodynamics to counter-select resistance. Antimicrob Agents Chemother 51:744-747. http://dx.doi.org/10.1128/AAC.00334-06.
8. MacGowan AP, Rogers CA, Holt HA, Bowker KE. 2003. Activities of moxifloxacin against, and emergence of resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 47:1088-1095. http://dx.doi.org/10.1128/AAC.47.3.1088-1095.2003.
9. Zhou J, Dong Y, Zhao X, Lee S, Amin A, Ramaswamy S, Domagala J, Musser JM, Drlica K. 2000. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutants. J Infect Dis 182:517-525. http://dx.doi.org/10.1086/315708.
10. Sindelar G, Zhao X, Liew A, Dong Y, Lu T, Zhou J, Domagala J, Drlica K. 2000. Mutation prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 44:3337-3343. http://dx.doi.org/10.1128/AAC.44.12.3337-3343.2000.
11. Jumbe N, Louie A, Leary R, Liu W, Deziel MR, Tam VH, Bachhawat R, Freeman C, Kahn JB, Bush K, Dudley MN, Miller MH, Drusano GL. 2003. Application of a mathematical model to prevent in-vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 112:275-285. http://dx.doi.org/10.1172/JCI200316814.
12. Tam VH, Louie A, Deziel MR, Liu W, Leary R, Drusano GL. 2005. Bacterial population responses to drug selective pressure: examination of garenoxacin against Pseudomonas aeruginosa. J Infect Dis 192:420-428. http://dx.doi.org/10.1086/430611.
13. Andes D, Craig WA. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 46:1665-1670. http://dx.doi.org/10.1128/AAC.46.6.1665-1670.2002.
14. Louie A, Fregeau C, Liu W, Kulawy R, Drusano GL. 2009. Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid (ELF) targets. Antimicrob Agents Chemother 53:3325-3330. http://dx.doi.org/10.1128/AAC.00006-09.
15. MacGowan AP, Reynolds R, Noel AR, Bowker KE. 2009. Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints. Antimicrob Agents Chemother 53:5181-5184. http://dx.doi.org/10.1128/AAC.00118-09.
16. Zhao X, Drlica K. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis 185:561-565. http://dx.doi.org/10.1086/338571.
17. Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH. 2003. In vitro pharmacodynamics evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother 47:1604-1613. http://dx.doi.org/10.1128/AAC.47.5.1604-1613.2003.
18. Tam VH, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN, Drusano GL. 2007. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis 195:1818-1827. http://dx.doi.org/10.1086/518003.
19. Drusano GL, Liu W, Brown DL, Rice LB, Louie A. 2009. Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus. J Infect Dis 199:219-226. http://dx.doi.org/10.1086/595739.
20. Jumbe NL, Louie A, Miller MH, Liu W, Deziel MR, Tam VH, Bachhawat R, Drusano GL. 2006. Quinolone efflux pumps play a central role in emergence of resistance to fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 50:310-317. http://dx.doi.org/10.1128/AAC.50.1.310-317.2006.
21. Louie A, Brown DL, Liu W, Kulawy RW, Deziel MR, Drusano GL. 2007. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob Agents Chemother 51:3988-4000. http://dx.doi.org/10.1128/AAC.00391-07.
22. Bowker KE, Garvey MI, Noel AR, Tomaselli SG, MacGowan AP. 2013. Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum. J Antimicrob Chemother 68:1130-1138. http://dx.doi.org/10.1093/jac/dks537.
23. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. 2004. Selection of a moxifloxacin dose that suppresses Mycobacterium tuberculosis resistance using an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 190:1642-1651. http://dx.doi.org/10.1086/424849.
24. Louie A, Deziel MR, Liu W, Drusano GL. 2007. Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy. Antimicrob Agents Chemother 51:2661-2667. http://dx.doi.org/10.1128/AAC.00073-07.
25. Louie A, Heine HS, Heine HS, VanScoy B, Eichas A, Files K, Fikes S, Brown DL, Liu W, Kinzig-Schippers M, Sörgel F, Drusano GL. 2011. Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance. Antimicrob Agents Chemother 55:822-830. http://dx.doi.org/10.1128/AAC.00818-10.
26. Louie A, Vanscoy B, Liu W, Kulawy R, Brown D, Heine HS, Drusano GL. 2011. Comparative efficacies of candidate antibiotics against Yersinia pestis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 55:2623-2628. http://dx.doi.org/10.1128/AAC.01374-10.
27. Deziel M, Heine H, Louie A, Kao M, Byrne WR, Bassett J, Miller L, Bush K, Kelley M, Drusano GL. 2005. Identification of effective antimicrobial regimens for use in humans for the therapy of Bacillus anthracis infections and post-exposure prophylaxis. Antimicrob Agents Chemother 49:5099-5106. http://dx.doi.org/10.1128/AAC.49.12.5099-5106.2005.
28. Louie A, Heine HS, Kim K, Brown DL, VanScoy B, Liu W, Kinzig-Schippers M, F Sörgel Drusano GL. 2008. Use of an in vitro model of Bacillus anthracis infection to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance. Antimicrob Agents Chemother 52:2486-2496. http://dx.doi.org/10.1128/AAC.01439-07.
29. Drusano GL, Okusanya OO, Okusanya AO, van Scoy B, Brown DL, Fregeau C, Kulawy R, Kinzig M, Sörgel F, Heine HS, Louie A. 2009. Impact of spore biology on the rate of kill and suppression of resistance in Bacillus anthracis. Antimicrob Agents Chemother 53:4718-4725. http://dx.doi.org/10.1128/AAC.00802-09.
30. Louie A, Bied A, Fregeau C, Van Scoy B, Brown D, Liu W, Bush K, Queenan AM, Morrow B, Khashab M, Kahn JB, Nicholson S, Kulawy R, Drusano GL. 2010. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic Pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother 54:2638-2645. http://dx.doi.org/10.1128/AAC.01721-09.
31. Drusano GL, Lodise TP, Melnick D, Liu W, Oliver A, Mena A, VanScoy B, Louie A. 2011. Meropenem penetration into epithelial lining fluid in mice and men and delineation of exposure targets. Antimicrob Agents Chemother 55:3406-3412. http://dx.doi.org/10.1128/AAC.01559-10.
32. Felton T, Goodwin J, O'Connor L, Sharp A, Gregson L, Livermore J, Howard SJ, Neely MN, Hope WW. 2013. Impact of bolus dosing versus continuous infusion of piperacillin and tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 57:5811-5819. http://dx.doi.org/10.1128/AAC.00867-13.
33. Bowker KE, Noel AR, Tomaselli SG, Elliott H, MacGowan AP. 2012. Pharmacodynamics of the antibacterial effect and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 56:5009-5015. http://dx.doi.org/10.1128/AAC.06111-11.
34. MacGowan AP, Noel AR, Tomaselli S, Bowker KE. 2013. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 57:2451-2456. http://dx.doi.org/10.1128/AAC.01386-12.
35. MacGowan AP, Bowker KE, Noel AR. 2008. Pharmacodynamics of the antibacterial effect and emergence of resistance to tomopenem, formerly RO4908463/CS-023, in an in vitro pharmacokinetic model of Staphylococcus aureus infection. Antimicrob Agents Chemother 52:1401-1406. http://dx.doi.org/10.1128/AAC.01153-07.
36. MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE. 2011. Pharmacodynamics of razupenem studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 55:1436-1442. http://dx.doi.org/10.1128/AAC.00936-10.
37. Gumbo T, Louie A, Liu W, Ambrose PG, Bhavnani SM, Brown D, Drusano GL. 2007. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. J Infect Dis 195:194-201. http://dx.doi.org/10.1086/510247.
38. Gumbo T, Louie A, Brown D, Ambrose PG, Bhavnani SM, Drusano GL. 2007. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 51:2329-2336. http://dx.doi.org/10.1128/AAC.00185-07.
39. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. 2007. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 51:3781-3788. http://dx.doi.org/10.1128/AAC.01533-06.
40. MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE. 2011. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 55:867-873. http://dx.doi.org/10.1128/AAC.00933-10.
41. Bowker KE, Noel AR, MacGowan AP. 2009. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J Antimicrob Chemother 64:1044-1051. http://dx.doi.org/10.1093/jac/dkp289.
42. Hansen GT, Metzler K, Drlica K, Blondeau JM. 2003. Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 47:440-441. http://dx.doi.org/10.1128/AAC.47.1.440-441.2003.
43. Drlica K, Malik M. 2003. Fluoroquinolones: action and resistance. Curr Top Med Chem 3:249-282. http://dx.doi.org/10.2174/1568026033452537.
44. Blondeau JM, Zhao X, G Hansen X, Drlica K. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 45:433-438. http://dx.doi.org/10.1128/AAC.45.2.433-438.2001.
45. Firsov AA, Lubenko IY, Smirnova MV, Strukova EN, Zinner SH. 2008. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother 52:1924-1928. http://dx.doi.org/10.1128/AAC.01371-07.
46. Croisier D, Etienne M, Bergoin E, Charles PE, Lequeu C, Piroth L, Portier H, Chavanet P. 2004. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy. Antimicrob Agents Chemother 48:1699-1707. http://dx.doi.org/10.1128/AAC.48.5.1699-1707.2004.
47. Drusano GL, Fregeau C, Liu W, Brown DL, Louie A. 2010. Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model. Antimicrob Agents Chemother 54:4368-4372. http://dx.doi.org/10.1128/AAC.00133-10.
48. Drusano GL, Vanscoy B, Liu W, Fikes S, Brown D, Louie A. 2011. Saturability of granulocyte kill of Pseudomonas aeruginosa in a murine model of pneumonia. Antimicrob Agents Chemother 55:2693-2695. http://dx.doi.org/10.1128/AAC.01687-10.
49. Drusano GL, Liu W, Fikes S, Cirz R, Robbins N, Kurhanewicz S, Rodriquez J, Brown D, Baluya D, Louie A. 2014. Interaction of drug- and granulocyte-mediated killing of Pseudomonas aeruginosa in a murine pneumonia model. J Infect Dis 210:1319-1324. http://dx.doi.org/10.1093/infdis/jiu237.
50. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group. 2003. Comparison of 8 vs 15 days of therapy for patients with ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588-2598. http://dx.doi.org/10.1001/jama.290.19.2588.
51. Drusano GL. 2004. Antimicrobial pharmacodynamics: the interactions between bug and drug. Nat Rev Microbiol 2:289-300. http://dx.doi.org/10.1038/nrmicro862.
52. Harshey RM, Ramakirishnan T. 1976. Purification and properties of DNA-dependent RNA polymerase from Mycobacterium tuberculosis H37RV. Biochim Biophys Acta 432:49-59. http://dx.doi.org/10.1016/0005-2787(76)90040-X.
53. Wehrli W, Knüsel F, Schmid K, Staehelin M. 1968. Interaction of rifampin with bacterial RNA polymerase. Proc Natl Acad Sci U S A 61:667-673. http://dx.doi.org/10.1073/pnas.61.2.667.